Ms. Arevalo is dedicated to obtaining just redress for her clients while holding individuals, corporations and entities responsible for defective and dangerous actions, products and pharmaceuticals. Ms. Arevalo has litigated and settled multiple cases involving the recalled DePuy ASR hips and is active in many multidistrict and coordinated litigations around the country involving defective drugs and medical devices, such as the DePuy Pinnacle hips, Wright Medical hips, Inferior Vena Cava (IVC) filters and Essure birth control. In addition to her mass torts practice, Ms. Arevalo handles catastrophic injury and wrongful death cases and manages the personal injury division of McCune Wright Arevalo, LLP.
Ms. Arevalo grew up in Southern California and graduated with honors from the University of California, Irvine. Immediately after graduating from Loyola Law School in Los Angeles, California, Ms. Arevalo joined McCune Wright Arevalo, LLP. For over 14 years she has worked diligently to help those who have been injured or wronged. In addition to her busy litigation practice, Ms. Arevalo is actively involved in the Consumer Attorneys of California (CAOC) and is a graduate of CAOC’s 2015 Leadership Academy. She is also involved in the Inland Empire Chapter of CAOC and the CAOC Women’s Caucus. She was selected as a Super Lawyers Rising Star in 2016, an honor bestowed on less than 2% of California attorneys aged 40 and younger. Ms. Arevalo is also a regular speaker for the Association of Certified Fraud Examiners given her experience in commercial litigation.
Ms. Arevalo has argued in front of the California Court of Appeals and has tried multiple cases to verdict. She is currently the managing partner at McCune Wright Arevalo, LLP. Ms. Arevalo spoke at the HarrisMartin MDL Conference on pharmaceutical and environmental mass tort litigation in Santa Barbara on March 30, 2016. She discussed the ongoing litigation against Essure, a potentially harmful birth control method. She will be speaking at the HarrisMartin MDL Conference in Washington, D.C. on September 28, 2016, to discuss the developments and progression of the Essure cases.